Autopsy report · NCT00693043

Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy

“Principal Investigator left the institution requested termination”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Lahey Clinic

Sponsor type

University, hospital or other

Conditions

Pain

Interventions

lidocaine hydrochloride

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
  “Principal investigator left the institution” (89% match in meaning)
• Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
  “Principal Investigator has left the institution” (87% match in meaning)
• Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders
  “the Principal Investigator left the institution” (87% match in meaning)
• Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
  “Original Principal Investigator left the institution.” (85% match in meaning)
• Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
  “The original principal Investigator left the institution.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.